Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03222349 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetics and Safety Study of Diazepam Buccal Film (DBF) in Pediatric Subjects With Epilepsy
A Phase 2 study of Epilepsy, sponsored by Aquestive Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 10
- Study locations
NCT03222349 is a Phase 2 study of Epilepsy that has completed, run by Aquestive Therapeutics. The registered enrollment target is 24 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (97% lower). The trial reports 10 study locations across 8 states.
The verdict
NCT03222349, a Phase 2 study of Epilepsy, has completed, sponsored by Aquestive Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 10
- Study locations
Study Summary
Open-label study to assess the pharmacokinetics of a single diazepam buccal film (DBF) dose in 3 age cohorts of pediatric patients with epilepsy (age 2-5 years, age 6-11 years, and age 12-16 years). Subjects in the 6-11 years and 12-16 years age cohorts received a single DBF dose during the interictal period (Period A) and ictal/peri-ictal period (Period B) with at least 14 days washout between doses. Subjects in the age 2-5 years age cohort received a single DBF dose only during the ictal/peri-ictal period (Period B).
Conditions Studied
Interventions
- DRUG Diazepam Buccal Film
Study Locations (10)
New York
- Icahn School of Medicine at Mount Sinai - New York
- University of Rochester - Rochester
Texas
- Dell Children's Medical Center - Austin
- Austin Epilepsy Care Center - Austin
Arizona
- University of Arizona - Tucson
Florida
- NW FL Clinical Research Group, LLC - Gulf Breeze
New Jersey
- Children's St. Peters University Hospital - New Brunswick
North Carolina
- Onsite Clinical Solutions LLC - Charlotte
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-08-31 |
| Est. Completion | 2020-03-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03222349
The ClinicalTrials.gov registry entry for NCT03222349 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (97% lower). The listed sponsor is Aquestive Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which Diazepam Buccal Film is the first listed.
NCT03222349 reports 10 study locations spanning 8 distinct geographic areas - top geographies include New York, Texas, Arizona.
Frequently Asked Questions
What is clinical trial NCT03222349 about?
NCT03222349 is a clinical study titled "Pharmacokinetics and Safety Study of Diazepam Buccal Film (DBF) in Pediatric Subjects With Epilepsy". Open-label study to assess the pharmacokinetics of a single diazepam buccal film (DBF) dose in 3 age cohorts of pediatric patients with epilepsy (age 2-5 years, age 6-11 years, and age 12-16 years). Subjects in the 6-11 years and 12-16 years age cohorts received a single DBF dose during the interict...
What is the current status of trial NCT03222349?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2017-08-31. Estimated completion is 2020-03-11.
What conditions does trial NCT03222349 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT03222349?
The interventions under investigation include: Diazepam Buccal Film (DRUG).
Who is sponsoring clinical trial NCT03222349?
This trial is sponsored by Aquestive Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03222349 being conducted?
This trial has 10 study locations across Arizona, Florida, New Jersey, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
RECRUITING · Phase 2
-
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
RECRUITING · Phase 2
-
RNS System LGS Feasibility Study
ACTIVE NOT RECRUITING · Phase 2
-
Study of an External Responsive Neurostimulator System on Epileptiform Activity
COMPLETED · Phase 2
-
Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI
COMPLETED · Phase 2
-
Hormone Replacement in Menopausal Women With Epilepsy
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.